Asia-Pacific fibrotic diseases treatment market is projected to register a substantial CAGR of 6.0%in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030. Market Segmentation: Asia-Pacific Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan, Rest of Asia-Pacific) Industry Trends and Forecast to 2030 Some of the major factors contributing to the growth of the Asia-Pacific fibrotic diseases treatment market are: • Rising prevalence of fibrotic diseases • Technological advancement in the treatment of fibrosis diseases Market Players: Some of the key market players in the Asia-Pacific fibrotic diseases treatment market are listed below: • Boehringer Ingelheim International GmbH • AbbVie Inc. • Bristol-Myers Squibb Company • Gilead Sciences, Inc. • Teva Pharmaceutical Industries Ltd. • Sandoz International GmbH

1 INTRODUCTION 33 1.1 OBJECTIVES OF THE STUDY 33 1.2 MARKET DEFINITION 33 1.3 OVERVIEW OF THE ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET 33 1.4 LIMITATIONS 35 1.5 MARKETS COVERED 35 2 MARKET SEGMENTATION 37 2.1 MARKETS COVERED 37 2.2 GEOGRAPHICAL SCOPE 38 2.3 YEARS CONSIDERED FOR THE STUDY 39 2.4 CURRENCY AND PRICING 39 2.5 DBMR TRIPOD DATA VALIDATION MODEL 40 2.6 MULTIVARIATE MODELLING 43 2.7 TREATMENT TYPE LIFELINE CURVE 43 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44 2.9 DBMR MARKET POSITION GRID 45 2.10 MARKET END USER COVERAGE GRID 46 2.11 VENDOR SHARE ANALYSIS 47 2.12 SECONDARY SOURCES 48 2.13 ASSUMPTIONS 48 3 EXECUTIVE SUMMARY 49 4 PREMIUM INSIGHTS 51 4.1 PORTER'S 5 FORCES 52 4.2 PESTEL ANALYSIS 53 5 EPIDEMIOLOGY 54 5.1 INCIDENCE OF ALL BY GENDER 54 5.2 TREATMENT RATE 54 5.3 MORTALITY RATE 54 5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55 5.5 PATIENT TREATMENT SUCCESS RATE 55 6 INDUSTRY INSIGHTS 56 6.1 PATENT ANALYSIS 56 6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56 6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56 6.4 KEY PRICING STRATEGIES 57 6.5 KEY PATIENT ENROLLMENT STRATEGIES 58 7 MERGERS AND ACQUISITIONS 60 7.1 LICENSING: 60 7.2 COMMERCIALIZATION AGREEMENTS 60 8 PIPELINE ANALYSIS 61 8.1 PHASE 1 61 8.2 PHASE 2 61 8.3 PHASE 3 61 9 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62 9.1 FDA APPROVALS 62 9.2 EMA APPROVALS 63 10 MARKET OVERVIEW 64 10.1 DRIVERS 66 10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66 10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66 10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67 10.2 RESTRAINTS 67 10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67 10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67 10.3 OPPORTUNITIES 68 10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68 10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68 10.4 CHALLENGES 69 10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69 10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69 11 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70 11.1 OVERVIEW 71 11.2 MEDICATION 73 11.2.1 INTEDANIB (OFEV) 74 11.2.2 PIRFENIDONE (ESBRIET) 74 11.3 ORGAN TRANSPLANTATION 74 11.4 OXYGEN THERAPY 75 11.5 OTHERS 76 12 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77 12.1 OVERVIEW 78 12.2 IDIOPATHIC PULMONARY FIBROSIS 81 12.3 HEPATIC CIRRHOSIS 81 12.4 RENAL FIBROSIS 82 12.5 CUTANEOUS FIBROSIS 83 12.6 OTHERS 84 13 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85 13.1 OVERVIEW 86 13.2 HOSPITALS 89 13.3 SPECIALTY CLINICS 90 13.4 ACADEMIC AND RESEARCH INSTITUTES 90 13.5 OTHERS 91 14 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92 14.1 OVERVIEW 93 14.2 HOSPITAL PHARMACY 96 14.3 RETAIL PHARMACY 96 14.4 OTHERS 97 15 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98 15.1 ASIA-PACIFIC 99 15.1.1 JAPAN 106 15.1.2 CHINA 108 15.1.3 INDIA 110 15.1.4 SOUTH KOREA 112 15.1.5 AUSTRALIA 114 15.1.6 SINGAPORE 116 15.1.7 THAILAND 118 15.1.8 MALAYSIA 120 15.1.9 INDONESIA 122 15.1.10 PHILIPPINES 124 15.1.11 VIETNAM 126 15.1.12 TAIWAN 128 15.1.13 REST OF ASIA-PACIFIC 130 16 ASIA PACIFIC FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 131 16.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 131 17 SWOT ANALYSIS 132 18 COMPANY PROFILE 133 18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 133 18.1.1 COMPANY SNAPSHOT 133 18.1.2 REVENUE ANALYSIS 133 18.1.3 COMPANY SHARE ANALYSIS 134 18.1.4 PRODUCT PORTFOLIO 134 18.1.5 RECENT DEVELOPMENTS 134 18.2 GENENTECH, INC. 135 18.2.1 COMPANY SNAPSHOT 135 18.2.2 COMPANY SHARE ANALYSIS 135 18.2.3 PRODUCT PORTFOLIO 136 18.2.4 RECENT DEVELOPMENTS 136 18.3 SANDOZ INTERNATIONAL GMBH 137 18.3.1 COMPANY SNAPSHOT 137 18.3.2 COMPANY SHARE ANALYSIS 137 18.3.3 PRODUCT PORTFOLIO 138 18.3.4 RECENT DEVELOPMENTS 138 18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 139 18.4.1 COMPANY SNAPSHOT 139 18.4.2 REVENUE ANALYSIS 139 18.4.3 COMPANY SHARE ANALYSIS 140 18.4.4 PRODUCT PORTFOLIO 140 18.4.5 RECENT DEVELOPMENTS 140 18.5 ACCORD HEALTHCARE U.S. 141 18.5.1 COMPANY SNAPSHOT 141 18.5.2 COMPANY SHARE ANALYSIS 141 18.5.3 PRODUCT PORTFOLIO 142 18.5.4 RECENT DEVELOPMENTS 142 18.6 ABBVIE INC. 143 18.6.1 COMPANY SNAPSHOT 143 18.6.2 REVENUE ANALYSIS 143 18.6.3 PRODUCT PORTFOLIO 144 18.6.4 RECENT DEVELOPMENTS 144 18.7 ALPINE IMMUNE SCIENCES 145 18.7.1 COMPANY SNAPSHOT 145 18.7.2 REVENUE ANALYSIS 145 18.7.3 PRODUCT PORTFOLIO 146 18.7.4 RECENT DEVELOPMENTS 146 18.8 BELLBROOK LABS 147 18.8.1 COMPANY SNAPSHOT 147 18.8.2 PRODUCT PORTFOLIO 147 18.8.3 RECENT DEVELOPMENTS 147 18.9 BIOMX 148 18.9.1 COMPANY SNAPSHOT 148 18.9.2 REVENUE ANALYSIS 148 18.9.3 PRODUCT PORTFOLIO 149 18.9.4 RECENT DEVELOPMENTS 149 18.10 BRISTOL-MYERS SQUIBB COMPANY 150 18.10.1 COMPANY SNAPSHOT 150 18.10.2 REVENUE ANALYSIS 150 18.10.3 PRODUCT PORTFOLIO 151 18.10.4 RECENT DEVELOPMENTS 151 18.11 CAMBER PHARMACEUTICALS, INC. 152 18.11.1 COMPANY SNAPSHOT 152 18.11.2 PRODUCT PORTFOLIO 152 18.11.3 RECENT DEVELOPMENTS 152 18.12 ENVEDA 153 18.12.1 COMPANY SNAPSHOT 153 18.12.2 PRODUCT PORTFOLIO 153 18.12.3 RECENT DEVELOPMENTS 153 18.13 GILEAD SCIENCES, INC. 154 18.13.1 COMPANY SNAPSHOT 154 18.13.2 REVENUE ANALYSIS 154 18.13.3 PRODUCT PORTFOLIO 155 18.13.4 RECENT DEVELOPMENTS 155 18.14 INTERCEPT PHARMACEUTICALS, INC. 156 18.14.1 COMPANY SNAPSHOT 156 18.14.2 REVENUE ANALYSIS 156 18.14.3 PRODUCT PORTFOLIO 157 18.14.4 RECENT DEVELOPMENTS 157 18.15 KITHER BIOTECH S.R.L. 158 18.15.1 COMPANY SNAPSHOT 158 18.15.2 PRODUCT PORTFOLIO 158 18.15.3 RECENT DEVELOPMENTS 158 18.16 PHARMAXIS LTD 159 18.16.1 COMPANY SNAPSHOT 159 18.16.2 REVENUE ANALYSIS 159 18.16.3 PRODUCT PORTFOLIO 160 18.16.4 RECENT DEVELOPMENTS 160 18.17 REDX PHARMA PLC. 161 18.17.1 COMPANY SNAPSHOT 161 18.17.2 REVENUE ANALYSIS 161 18.17.3 PRODUCT PORTFOLIO 162 18.17.4 RECENT DEVELOPMENTS 162 18.18 VERONA PHARMA PLC 163 18.18.1 COMPANY SNAPSHOT 163 18.18.2 REVENUE ANALYSIS 163 18.18.3 PRODUCT PORTFOLIO 164 18.18.4 RECENT DEVELOPMENTS 164 19 QUESTIONNAIRE 165 20 RELATED REPORTS 168